Could engineered immune cells free diabetics from insulin shots?

NCT ID NCT07528105

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a single infusion of genetically modified immune cells (CAR-T cells) designed to target and calm the immune attack that causes type 1 diabetes. Nine adults with early-stage type 1 diabetes will receive the cells and be monitored for safety, insulin needs, and beta-cell function. The goal is to see if this approach can preserve the body's ability to produce insulin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: allogeneic CD7-targeted CAR-T cells (RD13-02)
What this could lead to: If it works, this could point toward a way to preserve the body's own insulin production and reduce dependence on insulin injections for people with early type 1 diabetes.
What could go wrong: This is a very early, small trial (9 people) testing safety first. The treatment may not work, could cause serious side effects, and any benefit may be temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T1DM - TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T1DM - TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, 201508, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.